CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Hydroxychloroquine - Daily dosingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug494 Matched Placebo Hydroxychloroquine Wiki 1.00
drug935 blood samples Wiki 1.00
drug370 Hydroxychloroquine - Weekly Dosing Wiki 0.71

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D004660 Encephalitis NIH 1.00
D009410 Nerve Degeneration NIH 1.00
D003141 Communicable Diseases NIH 0.12
D007239 Infection NIH 0.08

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)

The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to cope with the increased demand. The availability of personal protective equipment is limited and reports of high risk procedures such as aerosol generating procedures (e.g. intubation for the sickest patients) is a source of great concern for infection transmission. Frontline NHS staff with direct patient contact have the highest likelihood of exposure to SARS-CoV-2 and development of COVID-19 disease. Efforts to protect these workers from development of COVID-19, using drugs to prevent the disease, require urgent evaluation.

NCT04352933 COVID-19 Drug: Hydroxychloroquine - Daily dosing Drug: Hydroxychloroquine - Weekly Dosing Other: Matched Placebo Hydroxychloroquine

Primary Outcomes

Description: Time taken for incidence of COVID-19 disease between Hydroxychloroquine and placebo arms

Measure: Time to positive COVID-19 disease

Time: Assessed up to 90 days

Secondary Outcomes

Description: Number of COVID-19 symptoms based on clinical guidelines and test positive infections per study arm

Measure: Number of COVID-19 test positive cases

Time: Assessed up to 90 days

Description: Number of test positive COVID-19 serological test positive cases per study arm

Measure: Number of COVID-19 serological test positive cases

Time: Assessed up to 90 days

Description: Severity based on hospitalisation

Measure: Severity of COVID-19 disease between each arm

Time: Assessed up to 90 days

Description: Number of common COVID-19 complications between arms

Measure: Number of common COVID-19 complications between each arm

Time: Assessed up to 90 days


No related HPO nodes (Using clinical trials)